NCT05791331尚未招募不适用
A Randomized Controlled Trial of Oscillatory Mechanics Versus Oxygenation-based Criteria for Surfactant Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 458
- 主要终点
- Days of respiratory support
研究概览
简要总结
This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:
- to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
- to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.
Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.
Study Arms:
A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 27 Weeks 至 33 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Gestational age (GA) ≥ 27+0 and < 33+0 weeks
- •Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥
- •Written parental consent obtained
- •Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care
排除标准
- •Major congenital anomalies
- •Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
- •Surfactant therapy prior to the study entry
- •Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
- •Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations...)
- •Any clinical condition which may place the infants at undue risk as deemed by clinicians
- •Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
- •Outborn patients
结局指标
主要结局
Days of respiratory support
时间窗: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Number of days of required respiratory support
次要结局
- Days to achieve full-enteral feeding(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- First surfactant administration(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Days of invasive respiratory support(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Patients intubated and mechanically ventilated(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Patients receiving multiple surfactant doses(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Days on supplemental oxygen(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Total cumulative oxygen exposure(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants developing air-leaks(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants developing prematurity-associated complications(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Days of hospitalization(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Days of non-invasive respiratory support(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants receiving more than 28 days of respiratory support(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants developing BPD(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants discharged home with oxygen or respiratory support(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
- Infants receiving postnatal steroids(From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months")
研究者
Anna Lavizzari
Principal Investigator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
相似试验
已完成
不适用
Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic RhinitisNasal CongestionNon-allergic RhinitisNCT03399721Chordate Medical279
已完成
不适用
Study of Effectiveness of Pold in Chronic Nonspecific Low Back PainMechanical Low Back PainNCT01591824Omphis Foundation50
进行中（未招募）
不适用
Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinorésistance et traités par bithérapie interféron pégylé ribavirine. - PEGLISTEUCTR2008-006225-14-FRANRS
进行中（未招募）
1 期
Essai clinique contrôlé randomisé, multicentrique, évaluant l'efficacité de deux médicaments homéopathiques (Dopamine 5 CH et Serotoninum muriaticum 5 CH) chez l'enfant TDAH âgé de 3 à 7 ans (6 ans et 11 mois). - HYP-HOPETDAH (Trouble Déficit de l'Attention Hyperactivité)EUCTR2010-020810-27-FRaboratoires BOIRO112
已完成
不适用
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)Dermatitis, AtopicNCT03672383Bayer42